Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
185
resultados
Última actualización
07/12/2025 [07:47:00]
Resultados 25 a 50 de 185
Resumen de: US2025321218A1
The present disclosure provides methods of selecting a treatment for an inflammatory bowel disease in a subject. In particular, using an indicator of epithelial absorption and metabolism the present disclosure provides method for determining the likelihood a subject is responsive or non-responsive to an inflammatory bowel disease therapeutic agent. The method includes providing a baseline measurement of a microvillus length in the small intestine of a subject, selecting a treatment for the subject according to a treatment criteria, and administering the treatment to the subject.
Resumen de: US2025319052A1
This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.
Resumen de: EP4632080A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: KR20250148382A
본 발명은 염증성 장질환(inflammatory bowel disease, IBD) 진단 및 치료를 위한 miRNA 바이오마커를 제공한다. 본 발명의 일 실시예에 따른 바이오마커는 염증성 장질환 진단용 조성물, 진단을 위한 정보 제공 방법, 염증성 장질환 예방 또는 치료용 약학 조성물, 염증성 장질환을 치료하는 방법 및 염증성 장질환 치료제의 스크리닝 방법에 활용될 수 있다.
Resumen de: US2025313613A1
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.
Resumen de: WO2025210486A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Resumen de: US2025313880A1
Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: WO2025202626A1
The present techniques relate to a breath analysis device and a system for using such a breath analysis device. We also describe a method for using the breath analysis device. The breath analysis device comprises a filtering mechanism (which may also be termed a filter stack) for removing interferent chemicals to increase the accuracy of detection, identification and quantification of specific chemicals. Exhaled human breath comprises a multiplicity of vapour phase chemicals and the function of the filtering mechanism is removal, retardation and separation of chemicals other than the specific chemicals to be determined by the sensing element(s). Removal, retardation and separation of the chemicals other than those of interest reduces error by reducing cross sensitivities when using broadly selective sensors such as metal oxide semiconductors. One example use of the breath analysis device may be to enable users who suffer from digestive health problems, particularly irritable bowel syndrome (IBS) or small intestinal bacterial overgrowth (SIBO), to monitor symptoms based on detection of specific chemicals such as hydrogen and/or methane in their breath over time.
Resumen de: AU2024236253A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: US2025305068A1
The present invention relates to a new biomarker of inflammatory bowel disease and its uses. The new biomarker is a ratio of Dialister spp. to Phascolarctobacterium spp. This biomarker can be used for diagnosis purpose of diseases or disorders associated with an intestinal dysbiosis, for stratifying patient population in a clinical trial, for selecting a subject that will benefit from a treatment, or for monitoring treatment response. The present invention further provides new therapeutic strategies.
Resumen de: US2025302891A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Resumen de: WO2025206567A1
The present invention provides a miRNA biomarker for diagnosing and treating inflammatory bowel disease (IBD). A biomarker according to one embodiment of the present invention can be utilized in a composition for diagnosing inflammatory bowel disease, a method for providing information for diagnosis, a pharmaceutical composition for preventing or treating inflammatory bowel disease, and a method for treating inflammatory bowel disease.
Resumen de: US2025304705A1
The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: CN120719010A
The invention discloses an intestinal microbial marker related to irritable bowel syndrome, a product and application of the intestinal microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized in that the enteric microbial marker comprises one or more of Bacteroides multiforme, Clostridium concealum, Bacteroides ovale and Streptococcus sativus, and the enteric microbial marker comprises one or more of the following components: Bacteroides multiforme, Clostridium concealum, Bacteroides ovale and Streptococcus sativus, and the enteric microbial marker comprises one or more of Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum and Lactobacillus plantarum. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing irritable bowel syndrome and a computer program product related to the irritable bowel syndrome. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of the irritable bowel syndrome, and provides a new tool for clinical diagnosis.
Resumen de: CN120713972A
The invention discloses a traditional Chinese medicine compound for treating bowel stagnation and a preparation method, and relates to the technical field of traditional Chinese medicine preparation, the compound is prepared from the following raw materials in parts by mass: 12 parts of fried hawthorn, 12 parts of medicated leaven, 9 parts of ginger processed pinellia, 9 parts of poria cocos, 9 parts of pericarpium citri reticulatae, 9 parts of fructus forsythiae, 9 parts of radish seed, 9 parts of immature bitter orange, 9 parts of rhizoma cyperi, 6 parts of mangnolia officinalis, 9 parts of scutellaria baicalensis, 6 parts of coptis chinensis, 25 parts of raw atractylodes macrocephala koidz and 12 parts of rhizoma atractylodis. The medicated leaven in the traditional Chinese medicine compound is fried, so that the carried stale gas can be removed, the bitter taste generated in the subsequent decocting process can be reduced, thin-layer identification is performed on the fried hawthorn and the rhizoma atractylodis, the ratio can be calculated according to the distance from an original point to the center of a main spot and the distance from the original point to the front edge of a developing solvent, and the specific value can be calculated. And the property of the compound is judged, so that the decocted liquid medicine can be improved, and the gastrin level of a patient taking the liquid medicine can be effectively increased.
Resumen de: CN120699897A
The invention discloses a method for separating colonic lamina propria cells of mice with colitis and application of the method. According to the method, separation of the propria neutrophile granulocyte on the colon tissue with the complete length is tried for the first time, and the total time required by cell separation is effectively shortened through multiple digestion reagents with different compositions, so that apoptosis of the neutrophile granulocyte caused by long-time exposure of an intestinal sample is effectively avoided; the problems of low cell yield, poor activity and the like are solved, and a new thought is provided for separation of the neutrophile granulocytes.
Resumen de: CN120695183A
The invention discloses application of CUL7 as a target spot in preparation of a medicine for preventing and/or treating colitis, and belongs to the technical field of medicine and pharmacology. The invention provides application of a CUL7 target spot in preparation of a medicine for preventing and/or treating colitis. The invention also provides application of CUL7 as a target spot in preparation of a preparation for diagnosing colitis, and application of a CUL7 gene inhibitor or a CUL7 protein inhibitor in preparation of a medicine for preventing and/or treating colitis. The invention proves the relationship between the CUL7 and the colitis, the CUL7 can be used as a target for preventing and treating the colitis, the CUL7 gene expression or the CUL7 intervention effect can be realized by utilizing any technology, the colitis can be effectively inhibited, and a basis is provided for the prevention, diagnosis and treatment of diseases.
Resumen de: CN120708939A
The invention discloses an inflammatory bowel disease curative effect prediction system based on multi-modal data, and relates to the field of medical information processing. The system comprises a multi-modal data acquisition module used for receiving multi-modal data; the text feature extraction module is used for determining a text feature vector by utilizing a text feature extraction model; the endoscopic intestinal mucosa feature recognition module is used for determining intestinal mucosa features by using an endoscopic intestinal mucosa feature recognition model; the image feature recognition module is used for determining iconography features by using an image feature recognition model; the pathological feature extraction module is used for determining pathological features by using the pathological recognition model; and the curative effect prediction module is used for predicting the curative effect of the biological agent based on the multi-modal data characteristics by using a Transform model and a full connection layer. Compared with the prior art, biological agent curative effect prediction based on clinical-pathology-endoscope-image multi-mode feature fusion is achieved, and the accuracy and clinical rationality of diagnosis and treatment decisions are improved.
Resumen de: WO2025199410A1
The disclosed method and system pertain to stratifying a patient population for precision medicine in Inflammatory Bowel Disease (IBD) treatment. The method involves accessing a multi-omic dataset comprising genomic, transcriptomic, and proteomic profiles of patient data. Machine learning algorithms are employed to analyze the dataset and identify biomarkers associated with a response to a drug for treating IBD. The patient population is stratified into phenotypic groups based on the identified biomarkers using unsupervised clustering. A patient population predicted to respond to the drug is defined based on the stratification and further analysis of patient metadata. The system includes a data storage unit and a processor configured to perform the method. The method and system can be used to optimize therapeutic interventions in IBD management.
Resumen de: CN120683281A
The invention discloses a microbial marker for treating irritable bowel on the basis of coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker is prepared from the following components: Butyrimonas faecalis, Odoribacter laneus, Parabacteroides verdea, Bacteroides eggerii, Phocaeia massiformis, Phocaeia dorrei, Phocaeia vulgaris, Bacteroides nordii, Phocaeia viscera, Muriaceae bacteria, Clostridium fesum, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces Through metagenome sequencing and a machine learning algorithm, the key microbial markers significantly related to intestinal stress symptom improvement in the coprophilous fungus transplantation treatment process are screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of irritable bowel.
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: WO2025193919A1
Methods of identifying a canine subject susceptible to inflammatory bowel disease, methods of treating or preventing inflammatory bowel disease in a canine subject, and compositions useful for treating or preventing inflammatory bowel disease in a canine subject are described herein.
Resumen de: US2025290143A1
Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.
Resumen de: TW202535470A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/ or diagnostic use in a subgroup of patients having ulcerative colitis.
Nº publicación: KR20250135709A 15/09/2025
Solicitante:
연세대학교산학협력단
Resumen de: KR20250135709A
본 발명은 장 질환 예방 또는 치료용 조성물 및 장 질환 진단을 위한 정보제공방법에 관한 것으로, 인간의 장내 마이크로바이옴 분석을 통해 장 질환과 관련있는 유효 균주를 선별하였으며, 이들 중 크론병 등 장 질환에 치료 효과가 있는 균주를 확인하였는 바, 질병 진단 또는 장 질환의 예방, 개선 및 치료에 유용하게 활용될 수 있다.
BOPI
Sede Electrónica
